EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Application of Deuterium in an M 1 Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422

Julie L Engers iD, Jinming Li, Changho Han iD, Madeline F Long iD, Alison R Gregro, Christopher C Presley, Jonathan W Dickerson, Weimin Peng, Hyekyung P Cho, Alice L Rodriguez iD, Zixiu Xiang iD, Olivier Boutaud und 8 weitere

ACS Chemical Neuroscience · 2025

DOI: 10.1021/acschemneuro.5c00119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Julie L Engers und 19 weiteren Autor:innen. Beteiligte Einrichtung: Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States. Hauptthemen laut MEDLINE: Deuterium, Drug Discovery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS, Vanderbilt University, ACADIA Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, we disclosed VU0467319, an M1 positive allosteric modulator (PAM) clinical candidate that had successfully completed a phase I single ascending dose clinical trial. Pharmacokinetic assessment revealed that, in humans upon increasing dose, a circulating, inactive metabolite constituted a major portion of the total drug-related area under the curve (AUC). One approach the team employed to reduce inactive metabolite formation in the back-up program was the kinetic isotope effect, replacing the metabolically labile C-H bonds with shorter, more stable C-D bonds. The C-D dipole afforded VU6045422, a more potent M1 PAM (human EC50 = 192 nM, 80% ACh Max) than its proteocongener VU0467319 (human EC50 = 492 nM, 71% ACh Max), and retained the desired profile of minimal M1 agonism. Overall, the profile of VU6045422 supported advancement, as did greater in vitro metabolic stability in both microsomes and hepatocytes than did VU0467319. In both rat and dog in vivo, low doses proved to mirror the in vitro profile; however, at higher doses in 14-day exploratory toxicology studies, the amount of the same undesired metabolite derived from VU6045422 was equivalent to that produced from VU0467319. This unexpected IVIVC result, coupled with less than dose-proportional increases in exposure and no improvement in solubility, led to discontinuation of VU0467319/VU6045422 development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeuteriumDrug DiscoveryAnimalsHumansDogsAllosteric RegulationRatsMaleHepatocytesMicrosomes, LiverRats, Sprague-DawleyDose-Response Relationship, Drug

Stichwörter der Autor:innen

cognitiondeuteriumisotopemetabolismmuscarinic acetylcholine receptor subtype 1 (M1)positive allosteric modulator (PAM)

Substanzen

Deuterium

Autor:innen und Institutionen

  • Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
  • Acadia Pharmaceuticals Inc., San Diego, California 92130, United States.
  • Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
  • Vanderbilt Brain Institute, Vanderbilt University, Nashville, Tennessee 37232, United States.
  • Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States.

ORCID-Profile: Julie L Engers, Changho Han, Madeline F Long, Alice L Rodriguez, Zixiu Xiang, Craig W Lindsley

Förderung

  • NIMH NIH HHS
  • Vanderbilt University
  • ACADIA Pharmaceuticals
  • William K. Warren Foundation
  • National Institute of Mental Health

Zitieren

APA

Engers, J. L., Li, J., Han, C., Long, M. F., Gregro, A. R., Presley, C. C., Dickerson, J. W., Peng, W., Cho, H. P., Rodriguez, A. L., Xiang, Z., Boutaud, O., O'Carroll, C., Dey, P. M., Burstein, E. S., Niswender, C. M., Rook, J. M., Conn, P. J., Engers, D. W., & Lindsley, C. W. (2025). Application of Deuterium in an M 1 Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00119

Vancouver

Engers JL, Li J, Han C, Long MF, Gregro AR, Presley CC, et al. Application of Deuterium in an M 1 Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00119

BibTeX
@article{Engers2025,
  author = {Engers, Julie L and Li, Jinming and Han, Changho and Long, Madeline F and Gregro, Alison R and Presley, Christopher C and Dickerson, Jonathan W and Peng, Weimin and Cho, Hyekyung P and Rodriguez, Alice L and Xiang, Zixiu and Boutaud, Olivier and O'Carroll, Colin and Dey, P Markus and Burstein, Ethan S and Niswender, Colleen M and Rook, Jerri M and Conn, P Jeffrey and Engers, Darren W and Lindsley, Craig W},
  title = {Application of Deuterium in an M 1 Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422},
  journal = {ACS Chemical Neuroscience},
  year = {2025},
  doi = {10.1021/acschemneuro.5c00119}
}
Kostenlos starten →